Our development pipeline illustrates the progress we’re making on Moderna’s clinical programs currently in development to create mRNA medicines for a wide range of diseases and conditions. We are proud of the advancements we’ve made in pioneering new vaccines and therapeutics that may have the potential to treat rare diseases like Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA), and prevent disease such as Cytomegalovirus (CMV), Zika and cancers. View the progress of our mRNA clinical pipeline below.

Modality
Program #
Program Indication
Preclinical development
Phase 1
Phase 2
Phase 3 and commercial
Moderna rights
Core modalities
Prophylactic Vaccines
mRNA-1273

Novel coronavirus
(SARS-CoV-2) vaccine

Progress: 100%
Progress: 100%
Progress: 100%
Progress: 50%

Worldwide
BARDA funded

mRNA-1647

Cytomegalovirus (CMV) vaccine

Progress: 100%
Progress: 100%
Progress: 50%

Worldwide

mRNA-1893

Zika vaccine

Progress: 100%
Progress: 100%

Worldwide
BARDA funded

mRNA-1653

hMPV/PIV3 vaccine

Phase 1b
(pediatrics)
Phase 1
(adults)
Progress: 100%
Progress: 99%

Worldwide

mRNA-1345

Pediatric respiratory syncytial virus (RSV) vaccine
Future respiratory combo

Progress: 100%
Progress: 40%

Worldwide

mRNA-1851

Influenza H7N9 vaccine

Progress: 100%
Progress: 99%

Worldwide
Advancing subject to funding

mRNA-1189

Epstein-Barr virus (EBV) vaccine

Progress: 65%

Worldwide

Systemic Secreted & Cell Surface Therapeutics
mRNA-1944

Antibody against Chikungunya virus

Progress: 100%
Progress: 100%

Worldwide

AZD7970

Relaxin
Heart failure

Progress: 65%

50-50 U.S. profit sharing; AZ to pay royalities on ex-U.S. sales

mRNA-6981

PD-L1
Autoimmune hepatitis

Progress: 65%

Worldwide

mRNA-6231

IL-2
Autoimmune disorders

Progress: 65%

Worldwide

Exploratory modalities
Cancer Vaccines
mRNA-4157

Personalized cancer vaccine (PCV)

Progress: 100%
Progress: 100%
Progress: 50%

50-50 global profit sharing with Merck

mRNA-5671

KRAS vaccine
CRC, NSCLC, pancreatic cancer

Progress: 100%
Progress: 40%

50-50 global profit sharing with Merck

Intratumoral Immuno-Oncology
mRNA-2416

OX40L
Solid tumors/lymphoma
Advanced ovarian carcinoma (Ph 2 cohort)

Solid tumors/
lymphoma
Ovarian
Progress: 100%
Progress: 100%
Progress: 50%

Worldwide

mRNA-2752

OX40L/IL-23/IL-36γ (Triplet)
Solid tumors/lymphoma

Progress: 100%
Progress: 40%

Worldwide

MEDI1191

IL-12
Solid tumors

Progress: 100%
Progress: 40%

50-50 U.S. profit sharing; AZ to pay royalties on ex-U.S. sales

Localized Regenerative Therapeutics
AZD8601

VEGF-A
Myocardial ischemia

Progress: 100%
Progress: 100%
Progress: 50%

AZ to pay milestones and royalties

Systemic Intracellular Therapeutics
mRNA-3927

PCCA/PCCB
Propionic acidemia (PA)

Progress: 100%

Worldwide

mRNA-3705

MUT
Methylmalonic acidemia (MMA)

Progress: 65%

Worldwide

mRNA-3283

PAH
Phenylketonuria (PKU)

Progress: 65%

Worldwide

mRNA-3745

G6Pase
Glycogen Storage Disorder
Type 1a (GSD1a)

Progress: 65%

Worldwide

*Life -cycle to mRNA-1893
Abbreviations: AZ, AstraZeneca; α-GAL, alpha galaxtosidase; CMV, cytomegalovirus; CRC, colorectal cancer; G6Pase, glucose 6-phosphatase; hMPV, human metapneumovirus; IL12, interleukin 12; IL23, interleukin 23; IL36γ, interleukin 36 gamma; MUT, methylmalonyl-CoA mutase; NSCLC, non-small cell lung cancer; PAH, phenylalanine hydroxylase; PCCA/PCCB, propionyl-CoA carboxylase subunit A/B; PCV, personalized cancer vaccine; PIV3, human parainfluenza 3; RSV, respiratory syncytial virus; VEGF-A, vascular endothelial growth factor A; VZV, varicella zoster virus.